Also, in patient-derived AML cells harboring MLL-AF9 fusion with FLT3-TKD mutation, sc-ATAC-Seq analysis also demonstrated loss of binding sites of the same TFs and log2 fold-decline in sc-ATAC-Seq peaks in the MLL-FP target genes but increase in the ITGAM and LY96 genes (Fig. 2E, F). This evidence concerns the gene KMT2A and acute myeloid leukemia.